Home » Stocks » KRTX

Karuna Therapeutics, Inc. (KRTX)

Stock Price: $99.42 USD -3.38 (-3.29%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $100.00 +0.58 (0.58%) Jan 27, 7:53 AM
Market Cap 2.67B
Revenue (ttm) n/a
Net Income (ttm) -52.32M
Shares Out 26.66M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $99.42
Previous Close $102.80
Change ($) -3.38
Change (%) -3.29%
Day's Open 104.31
Day's Range 97.64 - 105.81
Day's Volume 194,624
52-Week Range 60.41 - 117.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living w...

Business Wire - 2 weeks ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living w...

Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living w...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

InvestorPlace - 3 months ago

It’s a frothy market, so why not have a bit of fun while the good times roll? These risky stocks to buy have great potential.

Other stocks mentioned: APPS, BE, EXPI, INO, OSTK, VSLR
Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to...

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Business Wire - 5 months ago

BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc.

Business Wire - 7 months ago

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential t...

Zacks Investment Research - 8 months ago

Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research - 9 months ago

Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.

Other stocks mentioned: LVGO, PFSI, SFM, STRA
Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).

The Motley Fool - 10 months ago

COVID-19 and initial public offerings don’t go well together.

Other stocks mentioned: BYND, FB, LYFT, UBER
The Motley Fool - 11 months ago

The volatile biotech has been up and down since its massive gain back in November.

The Motley Fool - 1 year ago

The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.

ETF Trends - 1 year ago

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...

Other stocks mentioned: BYND, CRTX, IGMS, INMD, NXTC, PLMR, SWAV, TPTX
The Motley Fool - 1 year ago

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, APRE, BNTX, GKOS, INMD, NXTC, PLMR, RAPT, TPTX
Zacks Investment Research - 1 year ago

This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

Other stocks mentioned: BYND, SILK, TPTX, ZM
CNBC - 1 year ago

An index that tracks initial public offerings has outperformed the S&P 500 in what could be a historic year for stocks.

Other stocks mentioned: BYND, CHWY
The Motley Fool - 1 year ago

Is the stock a buy now that the price has dropped?

The Motley Fool - 1 year ago

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?

Other stocks mentioned: AXSM, KOD
InvestorPlace - 1 year ago

In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.

Seeking Alpha - 1 year ago

4 Biotech Neurology Stocks, As Biotechs March On

Other stocks mentioned: ACAD, NBIX, NERV
InvestorPlace - 1 year ago

Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Karuna Therapeutics

Seeking Alpha - 1 year ago

Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia Study

The Motley Fool - 1 year ago

Karuna Therapeutics Tests Our Theories!

Seeking Alpha - 1 year ago

Karuna Therapeutics: Fundraising Makes For Buying Opportunity

CNBC - 1 year ago

"We're cautiously optimistic given the robustness of the clinical data that we reported this week," Karuna Therapeutics CEO Dr. Steve Paul says.

CNBC Television - 1 year ago

Karuna Therapeutics soars on potentially 'game changing' new schizophrenia drug

Karuna CEO Dr.

The Motley Fool - 1 year ago

History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.

The Motley Fool - 1 year ago

The pharma company announced the pricing of a public stock offering.

The Motley Fool - 1 year ago

Positive clinical trial results recently sent this stock soaring, but can it climb further?

24/7 Wall Street - 1 year ago

Karuna Therapeutics Inc. (NASDAQ: KRTX) shares skyrocketed on Monday after the firm announced mid-stage results from its schizophrenia treatment.

Investors Business Daily - 1 year ago

Shares of Karuna Therapeutics have septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test.

The Motley Fool - 1 year ago

The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock.

The Motley Fool - 1 year ago

Some surprising events lifted these stocks.

Other stocks mentioned: PTON, YNDX
24/7 Wall Street - 1 year ago

When investors see a stock rise by close to 100%, they probably just assume it’s a corporate buyout.

InvestorPlace - 1 year ago

Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring. The post Karuna Therapeutics News: KRTX Stock Skyrockets 415%...

The Motley Fool - 1 year ago

The clinical-stage biopharmaceutical company announced really great phase 2 results for its lead pipeline candidate.

Market Watch - 1 year ago

Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial ...

Benzinga - 1 year ago

Shares of the thinly traded, small-cap biotech Karuna Therapeutics Inc (NASDAQ: KRTX) were moving higher Monday on a positive clinical trial readout.

GuruFocus - 1 year ago

Details the CEO buys this past week for the following companies: AXA Equitable Holdings, Liberty Latin America, Karuna Therapeutics, Esperion Therapeutics and Altus Midstream

Other stocks mentioned: ALTM, EQH, ESPR, LILA, LILAK
GuruFocus - 1 year ago

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Other stocks mentioned: CHRS, DDMXU, FND, HDS, MOTS, OCX

About KRTX

Karuna Therapeutics, a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2019
CEO
Dr. Steven M. Paul M.D.
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
KRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for KRTX stock is "Strong Buy." The 12-month stock price forecast is 130.82, which is an increase of 31.58% from the latest price.

Price Target
$130.82
(31.58% upside)
Analyst Consensus: Strong Buy